Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis

Oral cancer incidence increasing worldwide due to spread of human papillomavirus (HPV), Oral SexMillions of patients worldwide suffer from treatment-induced Oral Mucositis (OM)Existing OM therapies...
October 28, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia

BEVERLY, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to highlight preclinical data by...
October 14, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Partnering Provides Momentum For Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need

Convened first Joint Development Committee (JDC) meetingData generated to inform internal Brilacidin development efforts in Ulcerative ColitisGoal to develop oral Brilacidin to treat a wide continuum...
October 08, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases

BEVERLY, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of published...
October 03, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Clinical Trial of Oral Brilacidin in Ulcerative Colitis Program Expected to Commence in December; Top-Line Data in Q1 2020

BEVERLY, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...
September 30, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm

Objective to further unlock market potential of pipeline and determine the appropriate path forward to enhance shareholder valueLocust Walk is a global life sciences transaction firm with exceptional...
September 16, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon

BEVERLY, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD...
September 10, 2019 09:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Plans for Clinical Trial of Oral Brilacidin for Ulcerative Colitis Program in 4th Quarter 2019

BEVERLY, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that the...
July 29, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities

Company building on momentum from recently executed licensing agreement with Alfasigma S.p.A.Focus on transitioning to oral formulations of first-in-class drug candidates, and securing additional...
July 22, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis

BEVERLY, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right